Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1298–1300. doi: 10.1128/aac.40.5.1298

Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.

S Merali 1, K Chin 1, R W Grady 1, A B Clarkson Jr 1
PMCID: PMC163314  PMID: 8723489

Abstract

In a rat model of Pneumocystis carinii pneumonia, a 3-week infusion of deferoxamine producing concentrations in plasma of > or = 1.5 micrograms m-1 eliminated the trophozoite life cycle stage. Since this concentration is well below that routinely achieved in patients treated for iron overload, deferoxamine has promise as a therapy for AIDS-associated P.carinii pneumonia.

Full Text

The Full Text of this article is available as a PDF (185.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett M. S., Smith J. W. Pneumocystis carinii, an opportunist in immunocompromised patients. Clin Microbiol Rev. 1991 Apr;4(2):137–149. doi: 10.1128/cmr.4.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bedrossian C. W. Ultrastructure of Pneumocystis carinii: a review of internal and surface characteristics. Semin Diagn Pathol. 1989 Aug;6(3):212–237. [PubMed] [Google Scholar]
  3. Chatterton J. M., Joss A. W., Davidson M. M., Ho-Yen D. O. Why have Pneumocystis carinii trophozoites been ignored? J Clin Pathol. 1990 Apr;43(4):265–268. doi: 10.1136/jcp.43.4.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clarkson A. B., Jr, Sarić M., Grady R. W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep;34(9):1833–1835. doi: 10.1128/aac.34.9.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Day J. P., Ackrill P. The chemistry of desferrioxamine chelation for aluminum overload in renal dialysis patients. Ther Drug Monit. 1993 Dec;15(6):598–601. doi: 10.1097/00007691-199312000-00026. [DOI] [PubMed] [Google Scholar]
  6. Herbert V., Shaw S., Jayatilleke E., Stopler-Kasdan T. Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin. Stem Cells. 1994 May;12(3):289–303. doi: 10.1002/stem.5530120305. [DOI] [PubMed] [Google Scholar]
  7. Hershko C., Pinson A., Link G. Iron chelation. Blood Rev. 1990 Mar;4(1):1–8. doi: 10.1016/0268-960x(90)90011-g. [DOI] [PubMed] [Google Scholar]
  8. Lee P., Mohammed N., Marshall L., Abeysinghe R. D., Hider R. C., Porter J. B., Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos. 1993 Jul-Aug;21(4):640–644. [PubMed] [Google Scholar]
  9. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med. 1992 Dec 24;327(26):1853–1860. doi: 10.1056/NEJM199212243272606. [DOI] [PubMed] [Google Scholar]
  10. Merali S., Chin K., Del Angel L., Grady R. W., Armstrong M., Clarkson A. B., Jr Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1995 Sep;39(9):2023–2026. doi: 10.1128/aac.39.9.2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Merali S., Chin K., Grady R. W., Weissberger L., Clarkson A. B., Jr Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob Agents Chemother. 1995 Jul;39(7):1442–1444. doi: 10.1128/aac.39.7.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Summers M. R., Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol. 1979 Aug;42(4):547–555. doi: 10.1111/j.1365-2141.1979.tb01167.x. [DOI] [PubMed] [Google Scholar]
  13. Walzer P. D. Immunopathogenesis of Pneumocystis carinii infection. J Lab Clin Med. 1991 Sep;118(3):206–216. [PubMed] [Google Scholar]
  14. Weinberg G. A. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994 May;38(5):997–1003. doi: 10.1128/aac.38.5.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Weinberg G. A., Shaw M. M. Suppressive effect of deferoxamine on the growth of Pneumocystis carinii in vitro. J Protozool. 1991 Nov-Dec;38(6):223S–224S. [PubMed] [Google Scholar]
  16. Yoneda K., Walzer P. D. Attachment of Pneumocystis carinii to type I alveolar cells studied by freeze-fracture electron microscopy. Infect Immun. 1983 May;40(2):812–815. doi: 10.1128/iai.40.2.812-815.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES